SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma

Scott M. Schuetze, J. Kyle Wathen, David R. Lucas, Edwin Choy, Brian L. Samuels, Arthur P. Staddon, Kristen N. Ganjoo, Margaret Von Mehren, Warren A. Chow, David M. Loeb, Hussein A. Tawbi, Daniel A. Rushing, Shreyaskumar R. Patel, Dafydd G. Thomas, Rashmi Chugh, Denise K. Reinke, Laurence H. Baker

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

BACKGROUND Dasatinib exhibited activity in preclinical models of sarcoma. The Sarcoma Alliance for Research through Collaboration (SARC) conducted a multicenter, phase 2 trial of dasatinib in patients with advanced sarcoma. METHODS Patients received dasatinib twice daily. The primary objective was to estimate the clinical benefit rate (CBR) (complete response or partial response within 6 months or stable disease duration of ≥6 months) with a target of ≥25%. Patients were enrolled into 1 of 7 different cohorts and assessed by imaging every 8 weeks using Choi criteria tumor response and a Bayesian hierarchical design. For each subtype, enrollment was stopped after a minimum of 9 patients were treated if there was a

Original languageEnglish (US)
Pages (from-to)868-874
Number of pages7
JournalCancer
Volume122
Issue number6
DOIs
StatePublished - Mar 15 2016

    Fingerprint

Keywords

  • adaptive
  • Bayesian
  • Choi
  • dasatinib
  • phase 2
  • sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schuetze, S. M., Wathen, J. K., Lucas, D. R., Choy, E., Samuels, B. L., Staddon, A. P., Ganjoo, K. N., Von Mehren, M., Chow, W. A., Loeb, D. M., Tawbi, H. A., Rushing, D. A., Patel, S. R., Thomas, D. G., Chugh, R., Reinke, D. K., & Baker, L. H. (2016). SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer, 122(6), 868-874. https://doi.org/10.1002/cncr.29858